Celine Callens

Institut Curie

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Institut Curie

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Celine Callens has a total of 254 co-authors. Here are the top co-authors by number of shared publications:

Ivan Bièche
Department of Genetics, Institut Curie, Paris, France
53 shared publications
Sophie Vacher
Department of Genetics, Institut Curie, Paris Cité University, Paris, France
42 shared publications
Didier Meseure
Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France
33 shared publications
Eric Pasmant
Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris Cité, CARPEM, Paris, France
33 shared publications
Kinan Drak Alsibai
Platform of Investigative Pathology, Curie Institute, Paris, France
33 shared publications
Martial Caly
33 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Primary tumor types (A) and biopsy sites (B).
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 3 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Primary tumor types (A) and biopsy sites (B).
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Flow chart of the study. No further treatment = clinical deterioration.
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Flow chart of the study. No further treatment = clinical deterioration.
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Study design. RAF/MEK, rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase.
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Study design. RAF/MEK, rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase.
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Molecular gene targets validated by MBB for n = 72 patients (A) and corresponding targeted treatments received for n = 34 patients (B).
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 4 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Molecular gene targets validated by MBB for n = 72 patients (A) and corresponding targeted treatments received for n = 34 patients (B).
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Overall survival according to the number of prior lines of systemic treatment
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Overall survival according to the number of prior lines of systemic treatment
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
OS according to PFS ratio eligibility. OS was measured since inclusion (OS1).
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 5 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
OS according to PFS ratio eligibility. OS was measured since inclusion (OS1).
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
OS according to ECOG PS. OS was measured since inclusion (OS1).
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure 6 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
OS according to ECOG PS. OS was measured since inclusion (OS1).
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Overall survival according to the RMH score
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Overall survival according to the RMH score
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Representativeness of study participants
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Representativeness of study participants
Open Access
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Detailed characteristics of patients evaluable for the PFS ratio
Website
Google Scholar
- 25 September 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer
by Pauline du Rusquec, Célia Dupain, Romain Geiss, Marie-Paule Sablin, Zahra Castel-Ajgal, Philippe Cassier, Antoine Italiano, Edith Borcoman, Jerzy Klijanienko, Vincent Servois, et al.
Detailed characteristics of patients evaluable for the PFS ratio

Show all